semustine (methyl-CCNU) / BMS - LARVOL DELTA

NOVEL CLGAB VS BEAM-L CONDITIONING IN HIGH-RISK LYMPHOMA ASCT: A PROSPECTIVE STUDY ON LONG-TERM OUTCOMES (EHA 2026) - "Conditioning comprised: CLGAB: cladribine 5mg/m²/d (days -7 to -3), gemcitabine 1250mg/m² (day -7), cytarabine 1500mg/m² (days -6 to -5), busulfan 0.8mg/kg q6h (days -4 to -2). BEAM-L: bendamustine 200mg/m²/d (days -7 to -6) or semustine 300mg/m² (day -7), plus etoposide 100mg/m² q12h, cytarabine 200mg/m² q12h (both days -6 to -3), and melphalan 140mg/m² (day -2)...Summary/Conclusion The novel CLGAB conditioning regimen significantly improves long-term DFS and accelerates engraftment compared to BEAM-L, while demonstrating a favorable safety profile in ASCT for high-risk/R/R lymphoma. Its superior efficacy in DE-DLBCL highlights CLGAB as a promising optimized conditioning strategy worthy of further validation."

Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma

Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study. (PubMed, Ann Hematol) - "Patients received one of four regimens: BeEAM (bendamustine, etoposide, cytarabine, melphalan; n = 16), CBV (cyclophosphamide, oral semustine, etoposide; n = 12), CEAC (oral semustine, etoposide, cytarabine, cyclophosphamide; n = 16), or SEAM (oral semustine, etoposide, cytarabine, melphalan; n = 36). Multivariate Cox analysis identified pre-transplant partial remission as an independent adverse prognostic factor for PFS (HR: 4.864; 95% CI: 1.094-21.634, p = 0.038). Although the four carmustine-substituted conditioning regimens demonstrated similar efficacy outcomes for ASCT in lymphoma patients, their distinct toxicity profiles highlight the need for personalized regimen selection, particularly in the context of carmustine shortages."

Journal • Real-world evidence • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Oncology • Transplantation

EFFICACY AND SAFETY OF DECITABINE COMBINED WITH FB3 AS CONDITIONAL REGIMEN FOR ELDERLY/FRAIL ACUTE MYELOID LEUKEMIA PATIENT WITH ALLO-HSCT (EBMT 2026) - "The historical control group was AML patients with age older than 50 years old and HCT-CI score ≤2 points who used BU+CTX , cyclophosphamide for HLA-identical hematopoietic stem cell transplantation and semustine + busulfan + cyclophosphamide + cytarabine +rabbit anti-human thymocyte immunoglobulin for HLA haploidentical HSCT (haplo-HSCT). The decitabine combined with FB conditioning regimen demonstrated efficacy and safety in allogeneic hematopoietic stem cell transplantation for elderly or frail patients with AML."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Geriatric Disorders • Graft versus Host Disease • Hematological Malignancies • Infectious Disease • Leukemia • TP53

A clinical study on the use of thiotepa in combination with semustine and cytarabine for conditioning of autologous hematopoietic stem cell transplantation in primary central nervous system lymphoma (ChiCTR) - P=N/A | N=22 | Not yet recruiting | Sponsor: Henan Provincial People's Hospital; Henan Provincial People's Hospita,medical

New trial • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation • CD34

Efficacy and safety of bmetl regimen (Orelabrutinib plus Semustine, Temozolomide and Lenalidomide) with subsequent maintenance treatment in elderly/frail patients with CNSL (ASH 2025) - "After induction therapy, patients with objective response received sequential MT regimen (methotrexate 3 mg/m 2 , day 1; thiotepa 20 mg/m 2 , day 2) in a 21-day cycle for 2-4 cycles... BMeTL regimen with subsequent maintenance treatment is effective and well-tolerated for elderly/frail patients with CNSL. This study provides a potential novel strategy for this elderly/frail population."

Clinical • Agranulocytosis • CNS Lymphoma • Geriatric Disorders • Granulocytopenia • Hematological Malignancies • Infectious Disease • Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes (ASH 2023) - P2, P2/3 | "Azacytidine (AZA) combined with Venetoclax (VEN), showed a synergistic anti-tumor activity against several hematological malignancies, Therefore, we explored AZA+VEN (VA) combined with modified BuCy(mBuCy) (semustine, cytarabine, busulfan, and cyclophosphamide) conditioning regimen and assessed the safety and effectiveness...Out of the eleven patients, four had previously undergone Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, and one patient had received Blinatumomab...The VA combined with the mBuCy proves to be a effective and safe conditioning regimen for high-risk ALL and MDS patients. However, more patients are needed for follow-up and validation."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation

Efficacy and Safety of Decitabine Combined with FB3 As Conditional Regimen for Elderly/Frail Acute Myeloid Leukemia Patient with Allo-HSCT (ASH 2024) - "Methods A retrospective analysis of patients who underwent allo-HSCT in our center from June 2016 to April 2022 and were older than 50 years old or HCT-CI score ≥ 3 points was performed using decitabine combined with FB3 regimen .Our center designed decitabine combined with FB3 (Dec+FB3) as conditional regimen (decitabine 20mg/m2 × 5days, fludarabine 30mg/m2 × 5days, busulfan 130mg/m2 × 3days) for elderly/frail AML patients with allo-HSCT. The historical control group was AML patients with age older than 50 years old and HCT-CI score ≤2 points who used BU+CTX (busulfan 0.8mg/kg q6h x 4days, cyclophosphamide 60mg/kg x 2days for HLA-identical hematopoietic stem cell transplantation and semustine (0.2g/m2 x 1day) + busulfan (0.8mg/kg q6h x 3days) + cyclophosphamide (1.8g/m2 x 2days) + cytarabine (2g/m2 q12h x 2days) +rabbit anti-human thymocyte immunoglobulin (2.5mg/kg x 4days) for HLA haploidentical HSCT (haplo-HSCT)...Conclusion In the case that the age of..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cerebral Hemorrhage • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Geriatric Disorders • Graft versus Host Disease • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Liver Cancer • Liver Failure • Oncology • Solid Tumor

Evolution of conditioning regimens prior to autologous stem cell transplantation in lymphoma patients. (PubMed, Transl Oncol) - "As a classical conditioning regimen, BEAM (carmustine, etoposide, cytarabine, and melphalan) can eliminate minimal residual disease and achieve long-term disease-free survival...Alternative regimens such as GBC (gemcitabine, busulfan, and cyclophosphamide)/GBM (gemcitabine, busulfan, and melphalan), BeEAM (bendamustine, etoposide, cytarabine, and melphalan), and SEAM (semustine, etoposide, cytarabine, and melphalan) are safe and feasible. Data from studies combining these regimens with novel drugs are even more attractive. Ultimately, future conditioning regimens will show low toxicity, be highly efficient, and be personalizable with respect to lymphoma subtype and comorbidities."

Journal • Review • Hematological Malignancies • Lymphoma • Oncology • Transplantation

ORELABRUTINIB PLUS SEMUSTINE, TEMOZOLOMIDE AND LENALIDOMIDE (BMeTL) REGIMEN WITH SEQUENTIAL MAINTENANCE TREATMENT IN ELDERLY OR FRAIL PATIENTS WITH CNSL: A PHASE II STUDY (ICML 2025) - "After 4 cycles of induction therapy, complete response (CR) and partial response (PR) pts received sequential MT regimen (methotrexate, 3 mg/m2, day 1; thiotepa, 20 mg/m2, day 2) for 2–4 cycles in a 21-day cycle. BMeTL regimen sequential maintenance treatment resulted in promising efficacy and safety for elderly/frail pts with PCNSL and SCNSL. Additional data will be reported later."

Clinical • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • MYD88

Quantifying Nitrosoureas: Comprehensive Insights into Analytical Techniques Transforming Cancer Research. (PubMed, Crit Rev Anal Chem) - "This review provides a comprehensive overview of the analytical methodologies employed over the past forty years for the detection and quantification of five widely used nitrosourea-based anticancer drugs-carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), nimustine (NMT), and fotemustine (FM)-along with their metabolites. Furthermore, advancements in hybrid analytical techniques and their potential in enhancing the selectivity and sensitivity of NU detection are explored. This review aims to provide insights into the evolution of analytical approaches for nitrosourea-based drugs, highlighting their applications in pharmacokinetics, therapeutic drug monitoring, and environmental surveillance."

Journal • Review • Brain Cancer • Hematological Malignancies • Immunology • Lymphoma • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

MIGHT: Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: He Huang

New P1 trial • Bone Marrow Transplantation • Hematological Disorders • Transplantation

HIGHT: Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: He Huang

New P1 trial • Bone Marrow Transplantation • Hematological Disorders • Transplantation

Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis. (PubMed, Front Oncol) - "P1 and P2 received CAR-T cell infusion following a conditioning regimen of fludarabine and cyclophosphamide (FC) for lymphodepletion, while P3 received the SEAM (semustine, etoposide, cytarabine, and melphalan) regimen and autologous stem cell transplantation bridging CAR-T cell infusion. P1 and P2 achieved rapid complete remission (CR), whereas P3 initially exhibited stable disease a month after CAR-T infusion and subsequently achieved CR after local radiation salvage therapy and lenalidomide maintenance...Notably, during follow-up, these patients experienced complications associated with cirrhosis, including endoscopic variceal bleeding, HBV reactivation, or the diagnosis of hepatic malignancy. Our findings suggest that CAR-T therapy is applicable and effective for the treatment of DLBCL patients with HBV-related cirrhosis, albeit necessitating monitoring for potential hepatic complications."

Journal • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Fibrosis • Gastroenterology • Hematological Malignancies • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Peking University People's Hospital | Unknown status ➔ Recruiting | Trial completion date: Sep 2021 ➔ Sep 2025 | Trial primary completion date: Sep 2021 ➔ Sep 2025

Enrollment open • Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients. (PubMed, Ann Hematol) - "In terms of safety, the CEAC cohort had a lower incidence rate of grade 1-2 gastrointestinal hemorrhage (P = 0.023) and severe nausea (P = 0.007) compared with the BEAM cohort. In conclusion, the CEAC regimen seems to be a suitable alternative to the BEAM regimen for ASCT in DLBCL patients."

Journal • Retrospective data • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation